Cover Image

Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial

Show other versions (1)

Background: Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer (CRC) patients. We assessed the efficacy of personalized vitamin D3 supplementation (VIDS) for reducing inflammation in patients with low vitamin D status. Methods: In an ongoing randomized d...

Full description

Saved in:
Bibliographic Details
Main Authors: Gwenzi, Tafirenyika (Author) , Weber, Alexander N. R. (Author) , Trares, Kira (Author) , Vlaški, Tomislav (Author) , Slavic, Marija (Author) , Sha, Sha (Author) , Edelmann, Dominic (Author) , Caspari, Reiner (Author) , Bilsing, Bettine (Author) , Fischer, Harald (Author) , Fernandes-Almeida, Cristina-Maria (Author) , Czock, David (Author) , Schöttker, Ben (Author) , Brenner, Hermann (Author)
Format: Article (Journal)
Language:English
Published: 08 January 2026
In: British journal of cancer
Year: 2026, Volume: 134, Issue: 6, Pages: 874-880
ISSN:1532-1827
DOI:10.1038/s41416-025-03333-6
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41416-025-03333-6
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41416-025-03333-6
Get full text
Author Notes:Tafirenyika Gwenzi, Alexander N.R. Weber, Kira Trares, Tomislav Vlaski, Marija Slavic, Sha Sha, Edelmann Dominic, Reiner Caspari, Bettine Bilsing, Harald Fischer, Cristina-Maria Fernandes-Almeida, David Czock, Ben Schöttker and Hermann Brenner
Description
Summary:Background: Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer (CRC) patients. We assessed the efficacy of personalized vitamin D3 supplementation (VIDS) for reducing inflammation in patients with low vitamin D status. Methods: In an ongoing randomized double-blind, placebo-controlled trial in Germany, CRC patients who underwent surgery in the past year and had serum 25-hydroxyvitamin D levels < 60 nmol/L were randomly assigned to either a personalized loading dose of VIDS, followed by a maintenance dose of 2000 IU/day or a placebo for 12 weeks. Changes in serum interleukin-6 (IL-6), interferon-gamma (IFN-γ), and matrix metalloproteinase (MMP-1) were compared at the end of trial among 126 patients (65 in the placebo and 61 in the intervention group). Results: The VIDS group exhibited 39.3% reduction in IL-6 levels compared to the placebo group (95% CI: −54.9% to −18.2%; p = 0.001). The reductions observed in IFN-γ and MMP-1 due to VIDS were not statistically significant (−6.7%; p = 0.69 and −5.4%; p = 0.23, respectively). Conclusion: In CRC patients with low vitamin D status, VIDS reduces serum IL-6, a pro-inflammatory biomarker associated with poor prognosis. Further research should explore a potential supportive therapeutic role of VIDS in managing inflammation and improving CRC outcomes.
Item Description:Online veröffentlicht: 08. Januar 2026
Gesehen am 11.03.2026
Im Titel ist die Zahl "3" tiefgestellt
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/s41416-025-03333-6

Similar Items